-
Liverpool seal Jacquet deal, Palace sign Strand Larsen on deadline day
-
Trump says not 'ripping' down Kennedy Center -- much
-
Sunderland rout 'childish' Burnley
-
Musk merges xAI into SpaceX in bid to build space data centers
-
Former France striker Benzema switches Saudi clubs
-
Sunderland rout hapless Burnley
-
Costa Rican president-elect looks to Bukele for help against crime
-
Hosts Australia to open Rugby World Cup against Hong Kong
-
New York records 13 cold-related deaths since late January
-
In post-Maduro Venezuela, pro- and anti-government workers march for better pay
-
Romero slams 'disgraceful' Spurs squad depth
-
Trump urges 'no changes' to bill to end shutdown
-
Trump says India, US strike trade deal
-
Cuban tourism in crisis; visitors repelled by fuel, power shortages
-
Liverpool set for Jacquet deal, Palace sign Strand Larsen on deadline day
-
FIFA president Infantino defends giving peace prize to Trump
-
Trump cuts India tariffs, says Modi will stop buying Russian oil
-
Borthwick backs Itoje to get 'big roar' off the bench against Wales
-
Twenty-one friends from Belgian village win €123mn jackpot
-
Mateta move to Milan scuppered by medical concerns: source
-
Late-January US snowstorm wasn't historically exceptional: NOAA
-
Punctuality at Germany's crisis-hit railway slumps
-
Gazans begin crossing to Egypt for treatment after partial Rafah reopening
-
Halt to MSF work will be 'catastrophic' for people of Gaza: MSF chief
-
Italian biathlete Passler suspended after pre-Olympics doping test
-
Europe observatory hails plan to abandon light-polluting Chile project
-
Iran president orders talks with US as Trump hopeful of deal
-
Uncertainty grows over when US budget showdown will end
-
Oil slides, gold loses lustre as Iran threat recedes
-
Russian captain found guilty in fatal North Sea crash
-
Disney earnings boosted by theme parks, as CEO handover nears
-
Sri Lanka drop Test captain De Silva from T20 World Cup squad
-
France demands 1.7 bn euros in payroll taxes from Uber: media report
-
EU will struggle to secure key raw materials supply, warns report
-
France poised to adopt 2026 budget after months of tense talks
-
Latest Epstein file dump rocks UK royals, politics
-
Arteta seeks Arsenal reinforcement for injured Merino
-
Russia uses sport to 'whitewash' its aggression, says Ukraine minister
-
Chile officially backs Bachelet candidacy for UN top job
-
European stocks rise as oil tumbles, while tech worries weigh on New York
-
England captain Itoje on bench for Six Nations opener against Wales
-
Rahm says golfers should be 'free' to play where they want after LIV defections
-
More baby milk recalls in France after new toxin rules
-
Rosenior will not rush Estevao return from Brazil
-
Mercedes ready to win F1 world title, says Russell
-
Germany hit by nationwide public transport strike
-
Barca coach Flick 'not happy' with Raphinha thigh strain
-
WHO chief says turmoil creates chance for reset
-
European stocks rise as gold, oil prices tumble
-
Rink issues resolved, NHL stars chase Olympic gold at Milan
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the third quarter ended September 30, 2025, after the stock market closes on Thursday, November 13, 2025. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1739504&tp_key=71dd648c0e. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 20, 2025, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13756671.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
W.Nelson--AT